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deficiency, (2) after standard chemotherapy, (3) post- 
HSCT, (4) post-SOT, (5) inflammatory diseases/im- 
munosuppressive treatment, (6) HIV infection, (7) other 
groups. The recommendations will be outlined and are 
available on the RCPCH website. 
Conclusion: The introduction of the BPS should allow 
a consistent approach to immunisation of immuno- 
compromised children, and if this is confirmed at audit, 
will stimulate further research necessary to generate the 
solid evidence base that is required to support future 
recommendations. 
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Patients and methods: 246 cases were investigated to 
assess risk factors and outcome of infections, appearing 
in 36 neonates with very low birth weight (VLBW) 
<15OOg to other 210 neonates, appearing in 2 years in 
tertiary referral neonatal centre. 
Results: The analysis of types of cultures: blood cultures/ 
catheter. tips, showed that, the rate of bacteraemia/sepsis 
in <15OOg birth weight newborn infants (41.67% vs. 7.62, 
PsO.0001) was more higher than in those of >15OOg 
birth weight; umbilical swaps were more significantly 
observed in VLBW newborn infants than (40% vs. 
19.44%, PsO.029) <15OOg birth weight. According to 
the analysis of etiology there were differences between 
two groups for Klebsiella/Enterobacter infection rate, 
which showed higher rate of infection in VLBW infants 
(69.44 vs. 40.95, P<O.O027). According to the localisation 
of infection: bacteraemia/sepsis were more frequently 
prevalent and more significantly related to <15OOg birth 
weight newborn infants (36.11% vs. 5.71%, P10.0001) 
than >15OOg birth weight. Conjunctivitis (P10.0445), 
omphalitis (P10.031) were more frequently observed 
in >15OOg birth weight newborn infants, vice versa. 
Antibiotics used in the treatment of neonatal infection 
in both groups with significant univariate analysis 
were: penicillins (PsO.0237) meropenem (PsO.OOOl), 
ceftazidin (P10.02), ceftriaxon (P<O.o002), gentamicin 
(P<O.O0016), and netilmicin (P<O.OOOl) which were 
significantly and frequently observed in VLBW neo-nates. 
In an univariate analysis of mother’s risk factors, cerclage 
was more frequently observed (P%O.O005) in VLBW. 
Conclusion: The clinical significance of outcome were 
clear, since cure rates were logically higher among 
>15OOg birth weight newborn infants (98.57 vs. 88.89, 
P10.0099) than <15OOg birth weight, in term of death 
on underlying disease (overall mortality) (P10.0029). 
However PVL (P<O.O2), and IVH (IIIJIV.) (P10.0099) 
were significantly related to <15OOg birth weight new- 
born infants. 
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Background: One of the side effects reported on p- 
lactam antibiotic use is clinically significant bleeding. 
Among the mechanisms proposed for this adverse 
reaction was thrombocytopenia and platelets dysfunction. 
As of 1999 we use piperacillin/tazobactam as part of 
the empiric treatment for persumed sepsis. Since, pre- 
term infants are more prone to develop intraventricular 
hemorhage(IVH), some concerns have been raised 
as for the use of p-lactam antibiotics in this high risk 
population. 
Objective: To study the appearance of possible side 
effects of P/T use in term and preterm infants, parti- 
culary the incidence of IVH. 
Methods: Data from medical records were retrospectively 
collected from infants treated with P/T. Cranial ultra- 
sound (CUS) findings before, during and after the use of 
P/T were compared. The following side effects of the 
treatment were examined: clinical symptoms (allergic 
rash, gastrointestinal (GIT) symptoms, change in urine 
output, change in blood pressure) and blood tests 
(complete blood count, liver enzimes, bilirubin and 
creatinine). 
Results: During 1999-2001 a total of 165 episodes of P/T 
treatment were studied. In 55 episodes the treatment last 
for 5-14 days. Mean birth weight was 1690t900gr and 
GA was 31.7k4.7. CUS finding included 4 infants with 
IVH. All discovered during first 3 days of live and before 
the introduction of P/T. Low platelets(PLT) count was 
noticed in 38% of the patients(but was not related to P/T 
treatment). There were no evidence of allergic reaction, 
significant decrease in blood pressure, GIT symptomes 
or a change in blood test results. 
In 110 episodes the treatment last for 2-4 days, BW 
1300+550,GA 29.9k3.8. IVH was noticed in 15 (13.6%) 
infants all ocured before introducing P/T and 37 (33.6%) 
infants had low PLT(unrelated to the use of P/T). None 
of the above side effects were described. 
Conclusions: There was no increase in the rate of IVH 
with the treatment of P/T even in preterm infants with 
low PLT count. No other side effects occurred in this 
group of patients. More studies are required regarding 
the use of P/T in the neonate. 
